A new study reveals that dasatinib and quercetin (D+Q) cause demyelination in mice, raising safety concerns as over 30 clinical trials test the combo for age-related diseases. A study in Nature Aging ...
Dermatology is shifting from surface-level cosmetics to biology-driven interventions targeting aging hallmarks, with senolytics, epigenetic reprogramming, and biomimetic peptides leading the charge. D...
Phase 1 data for BGE-102 demonstrates significant reductions in hsCRP and inflammatory biomarkers, positioning it as a potential best-in-class therapy for cardiovascular risk and age-related inflammat...
A recent DGIST study shows somatostatin overexpression reduces inflammation and amyloid β in mice, suggesting repurposing existing drugs like octreotide could accelerate Alzheimer’s therapy and...
Phase 1 trial of RLS-1496 demonstrates safety with no severe adverse events and significant reduction in inflammatory markers, highlighting its potential as a senolytic therapy for skin conditions lik...
The FDA’s updated guidelines on cellular reprogramming, highlighted by Life Biosciences’ ER-100 trial for eye conditions, signal a pivotal shift that could accelerate anti-aging therapies,...
uPAR-targeted CAR T cell therapy shows promising results in solid tumors, with recent clinical trials and FDA designations advancing cancer immunotherapy towards precision medicine. Recent advancement...
Analyzing recent rapamycin clinical trials for anti-aging, focusing on optimal dosing, safety, and the shift from off-label use to evidence-based protocols in longevity research. New human trials on r...
Exploring the latest breakthroughs in partial reprogramming using OSKM factors for anti-aging, with insights from mouse studies and early clinical trials for eye diseases. Recent studies show partial ...
Recent studies show encapsulated mitochondria delivery using red blood cell membranes improves motor function and neuron survival in Parkinson’s disease models, offering hope for mitochondrial d...
